Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 4Thoracic 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Carcinoma, Renal Cell 14Urinary Bladder Neoplasms 11Prostatic Neoplasms 9Carcinoma, Transitional Cell 6Non-Muscle Invasive Bladder Neoplasms 4Urothelial Cancer 3Urologic Neoplasms 3Ureteral Neoplasms 3Sarcoma 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Melanoma 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Brain Neoplasms 3Uterine Cervical Neoplasms 2Urethral Neoplasms 2Thyroid Cancer, Papillary 2Salivary Gland Neoplasms 2Neuroblastoma 2Neoplasms 2Metastatic Castration-resistant Prostate Cancer 2Medulloblastoma 2Lung Neoplasms 2Kidney Neoplasms 2Head and Neck Neoplasms 2Glioma 2Esophageal Neoplasms 2Colorectal Neoplasms 2

Interventions

sacituzumab govitecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Carcinoma, Ovarian Epithelial × Genitourinary × Clear all
NCT01631552 2021-08-12

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Gilead Sciences

Phase 1/2 Completed
515 enrolled 28 charts 1 FDA
BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡